EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib

Charlotte Elvidge, Macy Heung, Thomas Clark, Coumaran Egile, Scott Myrand, Corey Russo, Gaia Schiavon, Shoko Shibata, Amy Spencer, Masakazu Toi, Anne Marie Velasco Roth, John Williamson und 2 weitere

Translational Oncology · 2027-01 · 75 · 103099

DOI: 10.1016/j.tranon.2026.103099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2027-01. Verfasst von Charlotte Elvidge und 13 weiteren Autor:innen. Beteiligte Einrichtung: Precision Diagnostics Development, Oncology R&D, AstraZeneca, Cambridge, UK. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study reports on analytical and clinical validation of the highly automated Ion Torrent™ Oncomine™ Dx Express Test (ODxET) for detecting PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer that may benefit from treatment with capivasertib plus fulvestrant. Analytical validation studies were completed using commercially sourced breast cancer tissue specimens to establish the ODxET assay detection capability (limit of detection, limit of blank), precision (repeatability, reproducibility), and effect of endogenous interfering substances for detecting PIK3CA/AKT1/PTEN alterations. Clinical validation was performed using 429 residual breast cancer tissue samples from the Phase 3 CAPItello-291 trial and progression-free survival (PFS) was analyzed for patients with PIK3CA/AKT1/PTEN-altered tumors, as detected by ODxET, and compared to efficacy outcomes from the CAPItello-291 study. Comparison of assay agreement between ODxET and FoundationOne®CDx (F1CDx) gave an overall, positive and negative percent agreement of 89.2%, 82.0%, and 96.6%, respectively. The 18% false negative rate observed with ODxET was largely attributable to limited detection of complex PTEN variants. PFS benefit was observed with capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with PIK3CA/AKT1/PTEN-altered tumors detected by ODxET (n=162; hazard ratio 0.55, 95% confidence interval [CI]: 0.38-0.78). This is similar to the observed PFS benefit in the population with PIK3CA/AKT1/PTEN-altered tumors identified by F1CDx in the CAPItello-291 trial (hazard ratio 0.49, 95% CI: 0.38-0.64). This study demonstrates the clinical utility of ODxET to identify patients with PIK3CA/AKT1/PTEN-altered tumors that may benefit from treatment with capivasertib plus fulvestrant.

Schlagwörter

Stichwörter der Autor:innen

BiomarkersBreast cancerCapivasertibNext-generation sequencingPrecision oncology

Autor:innen und Institutionen

  • Precision Diagnostics Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Research & Development, Thermo Fisher Scientific, Carlsbad, USA.
  • Precision Diagnostics Development, Oncology R&D, AstraZeneca, Barcelona, Spain.
  • Research & Development, Thermo Fisher Scientific, Ann Arbor, MI, USA.
  • Oncology R&D, AstraZeneca, Cambridge, UK.
  • Precision Medicine, Oncology R&D, AstraZeneca, Osaka, Japan.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Elvidge, C., Heung, M., Clark, T., Egile, C., Myrand, S., Russo, C., Schiavon, G., Shibata, S., Spencer, A., Toi, M., Roth, A. M. V., Williamson, J., Mumford, K., & Rugo, H. S. (2027). Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib. Translational Oncology, 75, 103099. https://doi.org/10.1016/j.tranon.2026.103099

Vancouver

Elvidge C, Heung M, Clark T, Egile C, Myrand S, Russo C, et al. Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib. Translational Oncology. 2027;75:103099. doi:10.1016/j.tranon.2026.103099

BibTeX
@article{Elvidge2027,
  author = {Elvidge, Charlotte and Heung, Macy and Clark, Thomas and Egile, Coumaran and Myrand, Scott and Russo, Corey and Schiavon, Gaia and Shibata, Shoko and Spencer, Amy and Toi, Masakazu and Roth, Anne Marie Velasco and Williamson, John and Mumford, Kyra and Rugo, Hope S},
  title = {Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib},
  journal = {Translational Oncology},
  year = {2027},
  volume = {75},
  pages = {103099},
  doi = {10.1016/j.tranon.2026.103099}
}
Kostenlos starten →